Chelsea Counsel Company’s Citius Pharmaceuticals CTXR Stock Holding History

Chelsea Counsel Company’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.8K	Hold	4,626	–	–	﹤0.01%	196
2026 Q1	$4.16K	Hold	4,626	–	–	﹤0.01%	192
2025 Q4	$3.6K	Hold	4,626	–	–	﹤0.01%	196
2025 Q3	$5.74K	Hold	4,626	–	–	﹤0.01%	187
2025 Q2	$7.36K	Hold	4,626	–	–	﹤0.01%	182
2025 Q1	$6.89K	Buy	+4,626	New	+$11.1K	﹤0.01%	177
2024 Q4	–	Sell	-11,252	Closed	-$141K	–	199
2024 Q3	$141K	Buy	11,252 +1,000	+10%	+$16.8K	0.07%	108
2024 Q2	$150K	Buy	10,252 +7,000	+215%	+$125K	0.07%	104
2024 Q1	$73K	Hold	3,252	–	–	0.04%	105
2023 Q4	$61.5K	Hold	3,252	–	–	0.03%	113
2023 Q3	$55.6K	Hold	3,252	–	–	0.03%	122
2023 Q2	$97.6K	Hold	3,252	–	–	0.05%	114
2023 Q1	$95.1K	Buy	+3,252	New	+$93.7K	0.05%	114

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MFS

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

Chelsea Counsel Company's CTXR Position: Q2 2026 in Review

Chelsea Counsel Company held its Citius Pharmaceuticals (CTXR) position steady in Q2 2026 at 4,626 shares worth $2.8K. The position accounts for ﹤0.01% of the portfolio, ranked #196.

Chelsea Counsel Company first reported a position in CTXR in Q1 2023 and has held it in 13 quarters since. The position peaked at $150K in Q2 2024. 42 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

Chelsea Counsel Company held 4,626 shares of Citius Pharmaceuticals worth $2.8K as of Q2 2026.
Chelsea Counsel Company left its Citius Pharmaceuticals share count unchanged in Q2 2026.
Citius Pharmaceuticals made up ﹤0.01% of Chelsea Counsel Company's portfolio in Q2 2026, its #196 holding.
Chelsea Counsel Company first reported a position in Citius Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
Chelsea Counsel Company's Citius Pharmaceuticals position peaked at $150K in Q2 2024.
42 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Chelsea Counsel Company's 13F filing for Q2 2026, filed 12 Aug 2026.